中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Small-molecule agents for cancer immunotherapy

文献类型：期刊论文

作者Wang, Fang10; Fu, Kai10; Wang, Yujue9; Pan, Can10; Wang, Xueping10; Liu, Zeyu10; Yang, Chuan10; Zheng, Ying8; Li, Xiaopeng6,7; Lu, Yu3,4,5
刊名ACTA PHARMACEUTICA SINICA B
出版日期2024-03-01
卷号14期号:3页码:905-952
关键词Cancer immunotherapy Small-molecule agents Immune checkpoints Oncogenic signaling Metabolic pathways Cytokine/chemokine signaling Antitumor immunity Tumor immune microenvironment
ISSN号2211-3835
DOI10.1016/j.apsb.2023.12.010
通讯作者To, Kenneth Kin Wah(kennethto@cuhk.edu.hk) ; Xia, Chenglai(xiachenglai@smu.edu.cn) ; Zhang, Jianye(jianyez@gzhmu.edu.cn) ; Shi, Zhi(tshizhi@jnu.edu.cn) ; Hu, Zeping(zeping_hu@tsinghua.edu.cn) ; Huang, Min(mhuang@simm.ac.cn) ; Fu, Liwu(fulw@mail.sysu.edu.cn)
英文摘要Cancer immunotherapy, exemplified by the remarkable clinical benefits of the immune checkpoint blockade and chimeric antigen receptor T-cell therapy, is revolutionizing cancer therapy. They induce long-term tumor regression and overall survival benefit in many types of cancer. With the advances in our knowledge about the tumor immune microenvironment, remarkable progress has been made in the development of small-molecule drugs for immunotherapy. Small molecules targeting PRR-associated pathways, immune checkpoints, oncogenic signaling, metabolic pathways, cytokine/che- mokine signaling, and immune-related kinases have been extensively investigated. Monotherapy of small- molecule immunotherapeutic drugs and their combinations with other antitumor modalities are under active clinical investigations to overcome immune tolerance and circumvent immune checkpoint inhibitor resistance. Here, we review the latest development of small-molecule agents for cancer immunotherapy by targeting defined pathways and highlighting their progress in recent clinical investigations. 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. This is an open access article under the CC BY-NC- ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
WOS关键词CHRONIC LYMPHOCYTIC-LEUKEMIA ; RECEPTOR TYROSINE KINASE ; TUMOR-ASSOCIATED MACROPHAGES ; ADVANCED BREAST-CANCER ; NON-HODGKIN-LYMPHOMA ; OPEN-LABEL ; DOUBLE-BLIND ; PANCREATIC-CANCER ; AVAILABLE THERAPY ; CELL CARCINOMA
资助项目National Natural Science Foundation of China[U21A20421] ; National Natural Science Foundation of China[82073882] ; National Natural Science Foundation of China[82073317] ; National Natural Science Foundation of China[81772540] ; National Natural Science Foundation of China[82272996] ; Key Project of Science Technology Program of Guangzhou (China)[2023B03J0029] ; National Key R&D Program of China[2022YFE0209700] ; Science and Technology Program of Guangzhou (China)[202201010819] ; Science and Technology Program of Guangzhou (China)[202206010081]
WOS研究方向Pharmacology & Pharmacy
语种英语
WOS记录号WOS:001300563000001
出版者INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
源URL[http://119.78.100.183/handle/2S10ELR8/313059]  
专题新药研究国家重点实验室
通讯作者To, Kenneth Kin Wah; Xia, Chenglai; Zhang, Jianye; Shi, Zhi; Hu, Zeping; Huang, Min; Fu, Liwu
作者单位1.Southern Med Univ, Affiliated Foshan Matern & Child Healthcare Hosp, Foshan 528000, Peoples R China
2.Chinese Univ Hong Kong, Sch Pharm, Hong Kong 999077, Peoples R China
3.Guangzhou Med Univ, Affiliated Hosp 5, Guangzhou 511436, Peoples R China
4.Guangzhou Med Univ, Sch Pharmaceut Sci, State Key Lab Resp Dis, Guangzhou 511436, Peoples R China
5.Guangzhou Med Univ, NMPA, Guangzhou Municipal & Guangdong Prov Key Lab Mol T, Guangzhou 511436, Peoples R China
6.Jinan Univ, Inst Biomed, Coll Life Sci & Technol, Natl Engn Res Ctr Genet Med,MOE Key Lab Tumor Mol, Guangzhou 510632, Peoples R China
7.Jinan Univ, Coll Life Sci & Technol, Natl Engn Res Ctr Genet Med, Dept Cell Biol,MOE Key Lab Tumor Mol Biol,Guangdon, Guangzhou 510632, Peoples R China
8.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
9.Tsinghua Univ, Tsinghua Peking Ctr Life Sci, Beijing Frontier Res Ctr Biol Struct, Sch Pharmaceut Sci, Beijing 100084, Peoples R China
10.Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangdong Esophageal Canc Inst,Guangdong Prov Clin, Guangzhou 510060, Peoples R China
推荐引用方式
GB/T 7714		 Wang, Fang,Fu, Kai,Wang, Yujue,et al. Small-molecule agents for cancer immunotherapy[J]. ACTA PHARMACEUTICA SINICA B,2024,14(3):905-952.
APA Wang, Fang.,Fu, Kai.,Wang, Yujue.,Pan, Can.,Wang, Xueping.,...&Fu, Liwu.(2024).Small-molecule agents for cancer immunotherapy.ACTA PHARMACEUTICA SINICA B,14(3),905-952.
MLA Wang, Fang,et al."Small-molecule agents for cancer immunotherapy".ACTA PHARMACEUTICA SINICA B 14.3(2024):905-952.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。